The effect of obesity on mid-term survival following coronary artery bypass surgery

Manoj Kuduvalli1, Antony D Grayson, Aung Y Oo

  • 1Department of Cardiothoracic Surgery,The Cardiothoracic Centre, Liverpool, UK. arashid@ccl-tr.nwest.nhs.uk

Insights

Obesity may increase mid-term mortality risk after coronary artery bypass grafting (CABG), despite no significant in-hospital risk. This study found a higher adjusted mortality hazard ratio for obese patients undergoing CABG.

Area of Science:

  • Cardiovascular Surgery
  • Obesity Research
  • Public Health

Background:

  • In-hospital mortality after coronary artery bypass grafting (CABG) is not significantly increased in obese patients.
  • The impact of obesity on mid-term survival following CABG remains under-investigated.

Purpose of the Study:

  • To investigate the association between obesity and mid-term survival after isolated coronary artery bypass grafting (CABG).

Main Methods:

  • Retrospective analysis of 4713 patients undergoing isolated CABG (1997-2001).
  • Obesity defined by Body Mass Index (BMI) ≥30 kg/m².
  • Mid-term survival assessed by linking patient records to the National Strategic Tracing Service; statistical analysis using Cox proportional hazards models.

Main Results:

  • A total of 330 deaths occurred during a mean follow-up of 2.4 years.
  • Crude mid-term mortality hazard ratio (HR) for obese patients was 1.09 (95% CI 0.86-1.39).
  • Adjusted HR for mid-term mortality in obese patients was 1.28 (95% CI 1.01-1.64; P=0.048), indicating a significant increase.

Conclusions:

  • Obesity is associated with a significant increase in mid-term mortality following coronary artery bypass grafting (CABG).
  • These findings suggest that while immediate outcomes may be unaffected, long-term survival can be compromised in obese patients post-CABG.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...